Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
OTLK•Outlook Therapeutics names new CFO ahead of U.S. launch
- Outlook Therapeutics Inc. appoints Kevin Lundquist as chief financial officer as it prepares for the U.S. commercial launch of Lytenava™.
- Outlook Therapeutics said Lawrence Kenyon will step down as CFO effective September 1, 2026.
